Jump to content

Bevo

Legacy Members
  • Posts

    14748
  • Joined

  • Last visited

Everything posted by Bevo

  1. Yeah, unfortunately doctors don’t know the pricing of all the things they prescribe. I prescribed Minocycline in tablets (I think) and later found out that the capsules were $100 cheaper.
  2. That isn’t true and if you spoke like that in public people would call you a prick. I was explaining the marketplace and you just want to whine and argue.
  3. Yeah, next time it will be different. And if he handles himself with the same maturity he has shown after he got into the dog house at Texas, I'm sure things will work out better for him with a change of scenery.
  4. Option number 3 - I'm just being a smartass since I wasn't sold on them when they were recruited.
  5. Insulin basically comes from three manufacturers who keep prices high. They have switched the market from less expensive human and animal insulins to more expensive insulin analogs. To combat the issue we need to get clinicians to prescribe lower-cost insulins. We also need to get biosimilar insulins through the FDA and figure out a way to get them distributed more efficiently. For every $100 spent on insulin, $40 goes to parties in the distribution chain. And finally, we need to figure out a way to address the patent system - the patent strategy to increase the patent life of a drug by filing additional patents I think is acceptable. But those additional patents probably should have shorter lifespans than the original patent. I don’t know how to do that but I’m sure @TwiceHorn has some ideas. I’m stuck using a phone so I can’t give you actual links on where pharma makes their money. One fact I can recall though is that generic drugs account for ~90% of prescription drugs dispensed, but they account for only ~30% of total United States pharmaceutical expenditures. So basically most pharmaceutical revenue comes from branded products. And, if you look at any annual report, it is pretty obvious that most of the profits come from their blockbusters still on patent. Also, notice all the price increases on those blockbusters which basically translates to pure profits for the pharma company in question. That can’t easily be done with generics. https://www.csrxp.org/big-pharma-earnings-watch-abbvie-amgen-and-gsk/
  6. I think you could have left out Butler/Dubose/Livingston - the only thing those guys can break out is a swell line dance.
  7. I'm just not sold on our 3rd wide receiver next year and that is without any injuries and Golden returning. Does the staff feel like one of the freshmen wide receivers can be an immediate impact guy? I guess it is hard to know, though, whether you have a Jeremiah Smith/Ryan Wingo or a Demond Demas/Evan Stewart. TE for fans seems to be a question mark as well. It's hard to know whether the staff feels like it has a solid 12 personnel package and whether it feels like it can replace Helms production. Any behind the scenes type info on the 2024 class on guys like Zina?
  8. @texifornia Did they ever tell us the severity of Derek Williams' knee injury and what they repaired at time of surgery?
  9. I thought Cole was - I did a quick google search and I didn't see it. Thanks for the clarification.
  10. safety will be fine. Corner is more of a question mark. Kobe Black, Wardell Mack, Santana Wilson, Jay'Vion Cole - most of those guys I haven't heard much about.
  11. Oh, kind of like Joe Burrow and Quinn Ewers.
  12. Fuck that. Let me know when Swift and Kelce go.
  13. Would you really hold that against her?
  14. Generics don’t make the largest companies profitable. In fact, I don’t know where things stand now, but 20 years ago, most pharmaceutical companies divested their OTC products and generics were an insignificant portion of sales. Basically all of their profits come from patented products and pharmaceutical companies attempt numerous workarounds to try to extend their patents as long as possible. Some of that has changed more recently due to the difficulty for companies to get generic biologics approved by the FDA, but still pharmaceutical companies don’t care about their generic products. All pharmaceutical profits are derived from innovation whether new targets or simply improved side effect profiles, method of delivery, etc. Anyway, it stands to reason that pharmaceutical companies strive to keep their product pipelines full. So, what do you think would happen if the industry were less profitable, had PEs similar to commodities, and earned exactly what the government thought was their right to earn? First, we would see good things - smaller sales forces, lower drug prices, less advertising. But later we would also see more mergers and acquisitions as the industry continued to mature. And we would see a decrease in development as the return on investment would justify fewer innovative, riskier products. Does this mean that innovation would die? Of course not. It would only slow down initially. However, in this scenario where government controls pharmaceutical prices, what happens as the government still has shortfalls in what it has budgeted to pay for pharmaceuticals? Well of course it would lower pharmaceutical prices even more. At some point without profits, development of pharmaceuticals comes to a crawl verses the rapid innovations that have occurred since penicillin was commercialized during WW2.
  15. My guess is that he led with NIL demands.
  16. Oregon and tOSU will be a battle. They should have the exact same chance to win it all. PSU will advance. We will advance. Georgia and Notre Dame will be a battle. Then it will be PSU vs the winner of the GA vs ND. And us vs the winner of OR vs OSU. PSU will lose because they aren't that good. And our game will be a tossup.
  17. Like alligator tackling?
  18. In conference play, we beat Mississippi State, OU, and Florida by a lot, Kentucky was somewhere in the middle, and A&M, Vanderbilt, and Arkansas we kept in the game through dumbassery. This is an away game against an opponent who would be middle of the pack in the SEC. It's possible that we could blow them out, but I think it is more likely that we will gift points and keep them in it similar to how the Clemson game went.
  19. Yeah, unfortunately this year Sark and our QB have a penchant for close games. Whether it is a timely interception, a poor coaching decision, a costly penalty, or a fumble, we have notoriously kept lesser teams feeling like they have a chance. We totally dominated Clemson and could have easily been up by 21+ points and forced them to panic or lay down, but that didn't happen. And it hasn't happened all season. I guess this time could be different, but I won't count on it. We will win, but I can't remember our last blowout victory.
  20. Closest I could find but no numbers: Ukraine Gets Major $266 Million F-16 Boost From US Published Dec 11, 2024 at 5:42 AM EST Updated Dec 12, 2024 at 11:33 AM EST Ukraine Approves New Droid Fighter Robot With Mounted Machine Gun By Hugh Cameron The U.S. has authorized a $266 million military package for Ukraine, aimed at supporting the services and repairs required to maintain the country's fleet of F-16 fighter jets. The announcement came on Tuesday from the U.S. Defense Security Cooperation Agency (DSCA), a branch of the Defense Department focused on weapons transfers and related support to allied nations. In its release, the DSCA said the State Department had approved the quarter-billion-dollar support package and Congress had been notified of the proposed sale, which when finalized will comprise "sustainment services and related equipment" for Kyiv's fighter jets. These include the Joint Mission Planning System, a software-based tool used by the Defense Department to coordinate missions for military aircraft and other assets, as well as maintenance services, personnel training and spare parts. "This proposed sale will support the foreign policy goals and national security objectives of the United States by improving the security of a partner country that is a force for political stability and economic progress in Europe," the DSCA said. It added that the sale will "improve Ukraine's capability to meet current and future threats by further equipping it to conduct self-defense and regional security missions with a more robust air defense capability" and that the country "will have no difficulty absorbing these articles and services into its armed forces." F-16 A Danish F-16 at the Farnborough International Airshow 2024, U.K. On Tuesday, the U.S. DSCA announced the approval of a $266 million military package for Ukrainian F-16s. John Keeble/Getty Images As well as facilitating the transfer of the jets to Ukraine from European nations, the U.S. has in the past helped to upgrade Kyiv's existing fleet. In late August, the U.S. Department of Defense's Defense Visual Information Distribution Service announced that jets supplied by the Netherlands and Denmark had been fitted with new systems allowing them to conduct "full-spectrum electromagnetic warfare." "The F-16s are operational and actively participating in Ukraine's combat operations," a State Department official told Newsweek. "The United States, along with its allies and partners, remains committed to supporting the expansion of Ukraine's F-16 program, which includes increasing the number of aircraft, as well as training pilots and maintainers." Ukraine announced that it had received its first batch of American-made F-16 fighter jets, originally developed for the U.S. Air Force, in August. Ukrainian President Volodymyr Zelensky expressed gratitude to the U.S., Denmark and the Netherlands for their support but did not specify which country supplied the shipment. Read more Ukraine Ukraine's NATO allies—including Denmark, the Netherlands, Norway and Belgium—have together promised to send nearly 100 F-16s to Kyiv, according to FlightGlobal, though it is unclear how many have been received or are yet operational. However, this sum is still insufficient, according to Ukraine. Zelensky told AFP in May that his country would require "120 to 130" F-16s to achieve "parity" with Russia's forces. When contacted for further information, a State Department official told Newsweek that they were unable to disclose the exact number of F-16s currently in Ukraine "for operational security reasons." On December 7, Zelensky said his country had received its second shipment of F-16s from Denmark, describing this as "an example of leadership in defending lives that sets Denmark apart." "The aircraft from the first batch, provided by the Danish people, are already intercepting Russian missiles, saving our people's lives and our infrastructure," Zelensky posted to X. "Now, our air shield has been further strengthened. If all partners were as determined, Russian terror could already have been made impossible."
  21. How many jets have been delivered to Ukraine? I heard lots of announcements when countries offered them.
  22. Ding ding ding. For the most part, research stops at research. As @TwiceHorn would attest, that doesn't help consumers. Ideas need to be developed and then commercialized. Those commercialized products are what we consume. There are tons of good ideas out there. Only the few that are well-funded, developed, and commercialized make it to market.
  23. Wrong, but I worked in the biotech industry for 15 years in licensing, business development, marketing management and consulting. So, I have enough experience to be considered an expert in university technology transfer, basic research, biotech companies, pharmaceutical companies and immunohistochemistry diagnostic companies (not much experience in medical equipment). And now I have 15 years of experience in patient care. Just since we are discussing the issue, besides being a consumer, what is your experience?
  24. Have you been watching this season?
  25. Also, we have a pretty big alumni base in Atlanta. The Mellow Mushroom would always have a big game watching party.
×
×
  • Create New...